Rituximab biosimilar - Opus BioAlternative Names: LG 966
Latest Information Update: 16 Jul 2016
At a glance
- Originator Lentigen Technology
- Developer Opus Bio
- Class Antineoplastics; Antirheumatics; Monoclonal antibodies
- Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported B cell lymphoma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in B-cell lymphoma in USA